ALLERGY THERAPEUTICS PLC

Director's Dealing • Nov 20, 2020

National Storage Mechanism | Additional information

RNS Number : 9406F

Allergy Therapeutics PLC

20 November 2020

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Director Dealings

20 November 2020 - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Peter Jensen, Non-Executive Chairman, has purchased 100,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 14 pence per Ordinary Share. Following the transaction, the total beneficial interest of Peter Jensen is 270,000 Ordinary Shares, representing 0.04% of the of the issued share capital of the Company to which voting rights are attached.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Peter Jensen

2

Reason for the notification

a)

Position/status

Non-Executive Chairman, Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Allergy Therapeutics plc

b)

LEI

213800PQ7AHK7KGVOE23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

0.1p ordinary shares

GB00B02LCQ05

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s) per Ordinary Share	Volume(s)
14 pence	100,000

d)

Aggregated information

N/A

e)

Date of the transaction

19 November 2020

f)

Place of the transaction

London Stock Exchange - AIM

-   ENDS   -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBRBDBDUBDGGC